Study guide
AKI and chronic kidney disease
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
AKI and chronic kidney disease
Key Takeaways Explain This Topic AI
CKD requires persistent kidney abnormalities for at least three months.
G3a CKD has an eGFR of 45–59 mL/min/1.73 m².
FENa has important limitations, including diuretic use and some intrinsic renal disorders.
Last updated: October 2026
Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
Renal parenchymal integrity and fluid-electrolyte equilibrium are essential for systemic haemodynamic stability. Acute deterioration in renal function and severe electrolyte derangements—predominantly hyperkalaemia and dysnatraemias—account for a major proportion of emergency admissions and inpatient medical consultations in Australian hospitals.
Acute Kidney Injury (AKI): Staging & Aetiology
The Kidney Disease: Improving Global Outcomes (KDIGO) criteria standardize the clinical definition and staging of acute kidney injury.
KDIGO Diagnostic Staging of AKI
Stage 1 : Serum Creatinine Criteria: Increase ≥ 26.5 μ mol/L \ge 26.5\ \mu\text{mol/L} ≥ 26.5 μ mol/L within 48 hours, or 1.5 − 1.9 × 1.5 - 1.9 \times 1.5 − 1.9 × baseline within 7 days; Urine Output Criteria: < 0.5 mL/kg/hour < 0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for 6 to 12 hours
Stage 2 : Serum Creatinine Criteria: 2.0 − 2.9 × 2.0 - 2.9 \times 2.0 − 2.9 × baseline serum creatinine; Urine Output Criteria: < 0.5 mL/kg/hour < 0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for ≥ 12 \ge 12 ≥ 12 hours
Stage 3 : Serum Creatinine Criteria: ≥ 3.0 × \ge 3.0 \times ≥ 3.0 × baseline, or serum creatinine ≥ 353.6 μ mol/L \ge 353.6\ \mu\text{mol/L} ≥ 353.6 μ mol/L , or initiation of renal replacement therapy; Urine Output Criteria: < 0.3 mL/kg/hour < 0.3\text{ mL/kg/hour} < 0.3 mL/kg/hour for ≥ 24 \ge 24 ≥ 24 hours, or anuria for ≥ 12 \ge 12 ≥ 12 hours
Aetiological Classification of AKI
Prerenal Azotaemia ( 55 − 60 % 55-60\% 55 − 60% ):
Decreased effective arterial blood volume and renal hypoperfusion with preserved parenchymal and tubular architecture.
Common Precipitants: Dehydration, haemorrhage, septic shock, congestive heart failure (cardiorenal syndrome), liver cirrhosis (hepatorenal syndrome).
The 'Triple Whammy' Drug Interaction: The combination of an ACE inhibitor or ARB (blocks angiotensin II-mediated efferent arteriolar vasoconstriction), an NSAID (blocks prostaglandin-mediated afferent arteriolar vasodilation), and a diuretic (induces intravascular hypovolaemia). This trio cripples intraglomerular hydrostatic pressure, precipitating acute prerenal failure.
Intrinsic Renal Injury ( 35 − 40 % 35-40\% 35 − 40% ):
Direct structural damage to glomeruli, tubules, interstitium, or renal microvasculature.
Acute Tubular Necrosis (ATN, 85 % 85\% 85% of intrinsic):
Ischaemic ATN: Prolonged, severe prerenal hypoperfusion leading to tubular epithelial hypoxia and necrosis.
Nephrotoxic ATN: Aminoglycosides (gentamicin), iodinated radiocontrast media, cisplatin, amphotericin B, or endogenous pigments (myoglobin from rhabdomyolysis [elevated serum creatine kinase, dipstick positive for 'blood' with zero RBCs on microscopy], haemoglobin from massive intravascular haemolysis, light chains in multiple myeloma).
Acute Interstitial Nephritis (AIN): Drug-induced allergic hypersensitivity ( > 75 % > 75\% > 75% of cases: penicillins, cephalosporins, sulfonamides, proton pump inhibitors, NSAIDs). Classic clinical triad: low-grade fever, maculopapular rash, and arthralgia/eosinophilia (present in < 30 % < 30\% < 30% ). Urine microscopy shows sterile pyuria, white blood cell casts, and eosinophiluria. Managed by prompt drug cessation ± \pm ± oral corticosteroids.
Acute Glomerulonephritis (Nephritic Syndrome): Immune-complex deposition or ANCA vasculitis; characterized by hypertension, oliguria, dysmorphic red blood cells, and red blood cell casts .
Postrenal / Obstructive Uropathy ( 5 − 10 % 5-10\% 5 − 10% ):
Mechanical blockage of urinary flow from the renal pelvis to the urethral meatus.
Bladder outlet obstruction (benign prostatic hyperplasia, prostate adenocarcinoma, neurogenic bladder, blocked urinary catheter) or bilateral ureteric obstruction.
First-Line Investigation: Urgent renal tract ultrasound to evaluate for hydronephrosis and assess post-void residual bladder volume.
Urinary Indices: Prerenal vs ATN Fractional Excretion of Sodium (FeNa) = Urine Na × Serum Creatinine Serum Na × Urine Creatinine × 100 \text{Fractional Excretion of Sodium (FeNa)} = \frac{\text{Urine Na} \times \text{Serum Creatinine}}{\text{Serum Na} \times \text{Urine Creatinine}} \times 100 Fractional Excretion of Sodium (FeNa) = Serum Na × Urine Creatinine Urine Na × Serum Creatinine × 100
Urine Sodium ( U Na \text{U}_{\text{Na}} U Na ) : Prerenal Azotaemia: < 20 mmol/L < 20\text{ mmol/L} < 20 mmol/L (avidity to conserve sodium); Acute Tubular Necrosis (ATN): > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L (impaired tubular reabsorption)
Fractional Excretion of Sodium (FeNa) : Prerenal Azotaemia: < 1 % < 1\% < 1% ; Acute Tubular Necrosis (ATN): > 2 % > 2\% > 2%
Fractional Excretion of Urea (FeUrea) : Prerenal Azotaemia: < 35 % < 35\% < 35% (preferred if patient takes loop diuretics); Acute Tubular Necrosis (ATN): > 50 % > 50\% > 50%
Urine Osmolality : Prerenal Azotaemia: > 500 mOsm/kg > 500\text{ mOsm/kg} > 500 mOsm/kg (intact concentrating ability); Acute Tubular Necrosis (ATN): < 350 mOsm/kg < 350\text{ mOsm/kg} < 350 mOsm/kg (isosthenuria)
Urea/creatinine: Interpret each result in its own units and clinical context. Do not apply a ratio of unconverted mmol/L urea and micromol/L creatinine as if dimensionless. Dehydration, GI bleeding, diet and kidney function all affect the pattern.
Urine Sediment Microscopy : Prerenal Azotaemia: Normal or Hyaline casts ; Acute Tubular Necrosis (ATN): 'Muddy brown' granular casts , epithelial cells
Chronic Kidney Disease (CKD) Staging & Complications
Chronic kidney disease is defined by persistent kidney damage or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 < 60\text{ mL/min/1.73 m}^2 < 60 mL/min/1.73 m 2 present for ≥ 3 months \ge 3\text{ months} ≥ 3 months .
The KDIGO GFR and Albuminuria Matrix
G1 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): ≥ 90 \ge 90 ≥ 90 ; Description: Normal or high (with other kidney damage); Albuminuria Stage: A1 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): < 3.0 < 3.0 < 3.0 ; Description: Normal to mildly increased
G2 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 60 − 89 60 - 89 60 − 89 ; Description: Mildly decreased; Albuminuria Stage: A2 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): 3.0 − 30.0 3.0 - 30.0 3.0 − 30.0 ; Description: Moderately increased (microalbuminuria)
G3a : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 45 − 54 45 - 54 45 − 54 ; Description: Mild-to-moderately decreased; Albuminuria Stage: A3 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): > 30.0 > 30.0 > 30.0 ; Description: Severely increased (macroalbuminuria)
G3b : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 30 − 44 30 - 44 30 − 44 ; Description: Moderately-to-severely decreased; Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —
G4 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 15 − 29 15 - 29 15 − 29 ; Description: Severely decreased; Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —
G5 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): < 15 < 15 < 15 ; Description: Kidney failure (End-stage kidney disease); Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —
Complications of Advanced CKD & Management
Anaemia of CKD:
Primarily driven by deficient erythropoietin (EPO) synthesis by renal peritubular interstitial fibroblasts. Normocytic, normochromic anaemia.
CKD anaemia: Check iron status and other correctable causes before choosing treatment. KDIGO 2026 iron criteria vary by dialysis status: do not use one universal ferritin target for every patient. Select oral or intravenous iron according to circumstances and response. ESA initiation considers symptoms, haemoglobin, transfusion risk and adverse effects; when used in adults, keep the haemoglobin target below 115 g/L rather than normalising it. Monitor iron indices, blood pressure and response.
CKD-Mineral and Bone Disorder (CKD-MBD):
CKD mineral/bone disorder: Phosphate retention and reduced active vitamin D contribute to altered calcium/PTH and bone turnover. Interpret serial calcium, phosphate and PTH together. Calciphylaxis is a distinct severe multifactorial disorder, not synonymous with ordinary vascular calcification.
Secondary hyperparathyroidism: Cinacalcet increases calcium-sensing receptor sensitivity, suppressing PTH; it does not inhibit that receptor. In non-dialysis CKD, trends in calcium, phosphate and PTH guide management. Routine calcitriol for every stage 3–5 patient or a normal-laboratory PTH target for stage 4 is inappropriate.
CKD acidosis: KDIGO 2024 advises considering treatment when acidosis has potential clinical consequences, for example bicarbonate below 18 mmol/L. Dose and monitor to avoid hypertension, fluid overload or excessive correction; 22 is not a universal mandatory drug-treatment threshold.
Cardiovascular Risk Reduction: Cardiovascular disease is the single leading cause of death in CKD. Blood pressure targets < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg using an ACE inhibitor or ARB (reduces intraglomerular pressure and proteinuria) plus an SGLT2 inhibitor (empagliflozin/dapagliflozin) for cardiovascular and renal protection.
Primary references (checked 7 October 2026): KDIGO CKD guidance .
KDIGO 2026 anaemia guideline updates iron and ESA decisions.